NVSEF News and Press, Novartis Ag Basel Akt From 04/26/22

Novartis AG (NVS) Q1 2022 Earnings Conference Call April 26, 2022 08:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Simon ...

The following slide deck was published by Novartis AG in conjunction with their 2022 Q1 earnings call. For further details see: Novartis AG 2022 Q1 - Results - Earnings Call Presentation

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD. RGX202 is the hidden asset, poised to make waves in the coming years. For further details see: Regenxbi...

BCRX halted enrollment in 3 trials of BCX9930 following elevated serum creatine in some patients, which indicates kidney impairment. While Orladeyo is doing very well, BCX9930 was BioCryst's pipeline future. With strong competition from Novartis and soliris biosims, BCX9930's pros...

The primary and secondary endpoints for HOPE-B were met when patients with Hemophilia B were treated with etranacogene dezaparvovec. Marketing applications for etranacogene dezaparvovec for the treatment of patients with Hemophilia B will be submitted in both the U.S. and EU in the 1s...

Analysts continue to disbelieve that the Pfizer/BioNTech Comirnaty vaccine can have a future, while reality shows boosters are needed. Pfizer’s earnings from Comirnaty continue to distort the price of Pfizer stock; this will continue. The more difficult issue is to understa...

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...

CRSP needs to make tough decisions regarding the loss of critical CRISPR patents in the US. CRSP differentiates itself by creating allogeneic CAR-T therapy allowing mass production, off-shelf availability, and potentially low production cost. The company is the wealthiest CRISPR b...

After poor performance during 2015 to 2018, IXJ reshuffled its portfolio. Price return in the past 3 years is good and even better in the longer period. Price multiples suggest that IXJ is neither undervalued nor overvalued. For further details see: IXJ: A Healthcare ETF...

Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...